GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

PPI deprescribing

Company
Duke University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for PPI deprescribing and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06129474

    Deprescribing Inappropriate Proton Pump Inhibitors

    Not yet reported University of Bern 400 participants Est. completion 2027-12-31 2 sites Stand-alone
    Other conditions: Inappropriate Prescribing, Reflux Disease, Proton Pump Inhibitors
    View official trial listing →
  • Completed NCT NCT04255823

    Efficacy of a Multi-faceted Intervention to Deprescribe Proton Pump Inhibitors (PPI) in Primary Care: a Population-based, Pragmatic, Cluster-randomized Controlled Trial.

    Not yet reported Nantes University Hospital 34000 participants Est. completion 2021-12-15 1 site Stand-alone
    Other conditions: Proton Pump Inhibitors, Deprescription
    View official trial listing →
  • Completed NCT NCT04513834

    Efficacy of a Multi-faceted Intervention Combining an Educational Outreach Visit to General Practitioners and Patient Education Material to Deprescribe Proton Pump Inhibitors (PPI): a Population-based, Pragmatic, Cluster-randomized Controlled Trial

    Not yet reported Nantes University Hospital 25000 participants Est. completion 2023-12-19 1 site Stand-alone
    Other conditions: Proton Pump Inhibitors, Deprescription
    View official trial listing →
  • Completed NCT NCT05070351

    Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy

    Not yet reported, Not yet reported Duke University 33 participants Est. completion 2025-06-02 1 site Stand-alone
    Other conditions: Hepatic Encephalopathy
    View official trial listing →
  • Active, not recruiting NCT NCT05629143

    Primary carE PPi dEprescRibing Trial

    Not yet reported Universitaire Ziekenhuizen KU Leuven 724 participants Est. completion 2026-06-01 1 site
    Other conditions: Heartburn, Dyspepsia, Reflux
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.